Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

Abroad (travel likely)RecruitingPHASE2

Conditions

Non-Small Cell Lung Cancer · Epidermal Growth Factor Receptor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Pusan National University Hospital, Busan, South Korea

Study leads

Mi-Hyun Kim
Principal Investigator
Pusan National University Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV · Non-small Cell Lung Cancer Recurrent

Abroad (travel likely)RecruitingPHASE1, PHASE2

St Louis, United States

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Unresectable Melanoma · Metastatic Melanoma · Stage III Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · Miami, United States

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Houston, United States